PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. (Q64903999)

30 June 2019

title

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. (English)

1 reference

30 June 2019

author name string

Megan Morisada

1

1 reference

30 June 2019

Paul E Clavijo

2

1 reference

30 June 2019

Ellen Moore

3

1 reference

30 June 2019

Lillian Sun

4

1 reference

30 June 2019

Michael Chamberlin

5

1 reference

30 June 2019

Carter Van Waes

6

1 reference

30 June 2019

James W Hodge

7

1 reference

30 June 2019

James B Mitchell

8

1 reference

30 June 2019

Jay Friedman

9

1 reference

30 June 2019

Clint T Allen

10

1 reference

30 June 2019

publication date

27 November 2017

1 reference

30 June 2019

published in

OncoImmunology

1 reference

30 June 2019

volume

7

1 reference

30 June 2019

issue

3

1 reference

30 June 2019

page(s)

e1395996

1 reference

30 June 2019

Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line

cites work

1 reference

12 December 2020

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

12 December 2020

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

1 reference

12 December 2020

Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer

1 reference

12 December 2020

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

12 December 2020

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

12 December 2020

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

12 December 2020

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

1 reference

12 December 2020

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 December 2020

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

1 reference

12 December 2020

ERK1/2 regulation of CD44 modulates oral cancer aggressiveness

1 reference

12 December 2020

Maximizing tumor immunity with fractionated radiation

1 reference

12 December 2020

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation

1 reference

12 December 2020

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects

1 reference

12 December 2020

Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer

1 reference

12 December 2020

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

12 December 2020

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

1 reference

12 December 2020

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

12 December 2020

Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells

1 reference

12 December 2020

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

1 reference

12 December 2020

Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.

1 reference

12 December 2020

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

1 reference

12 December 2020

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

1 reference

12 December 2020

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer

1 reference

12 December 2020

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.

1 reference

12 December 2020

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

12 December 2020

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

1 reference

12 December 2020

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

12 December 2020

Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

1 reference

12 December 2020

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

1 reference

12 December 2020

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

1 reference

12 December 2020

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells

1 reference

12 December 2020

10.1080/2162402X.2017.1395996

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

5790397

1 reference

30 June 2019

PubMed publication ID

29399393

1 reference

30 June 2019